Bisphosphonates

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Bisphosphonates.php on line 2
Bisphosphonates

LE WE PMID CA

Bisphosphonates

3308

Bisphosphonat

Bisphosphonates

Bone (BASKET)

Bone (Metastasis)

Cinacalcet

Fibrous dysplasia

Jaws (Osteonecrosis)

Mammary gland (Neoplasia)

Neoplasia (Tumor biology and immunology)

Osteoclasts

Osteogenesis imperfecta

Osteoporosis

Prostate (Neoplasia)

PTH (Hyperparathyreoidism BASKET)

Raloxifene

Tooth (Implantates)

2002 1	Gastric and duodenal safety of daily alendronate. [11966346] Arch Intern Med 162(8): 936-42 (2002)
2001 2	Risedronate: a clinical review. [11176760] Arch Intern Med 161(3): 353-60 (2001)
2010 3	Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. [20694061] Core Evid 4(-): 13-23 (2010)
1973 4	Diphosphonates. Experimental and clinical aspects. [4632759] J Bone Joint Surg Br 55(1): 66-86 (1973)
2008 5	Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. [17906299] Ann Oncol 19(3): 420-32 (2008)
2007 6	Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. [17591816] Ann Oncol 18 Suppl 6(-): vi168-72 (2007)
2007 7	New developments of aminobisphosphonates: the double face of Janus. [17591815] Ann Oncol 18 Suppl 6(-): vi164-7 (2007)
2006 8	Management of the adverse effects associated with intravenous bisphosphonates. [16547070] Ann Oncol 17(6): 897-907 (2006)
2006 9	Bisphosphonates and metastatic bone disease. [16608996] Ann Oncol 17 Suppl 2(-): ii91-95 (2006)
2003 10	The antineoplastic role of bisphosphonates: from basic research to clinical evidence. [14504045] Ann Oncol 14(10): 1468-76 (2003)
2007 11	The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. [17311345] Cancer 109(6): 1090-6 (2007)
2005 12	Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. [15929121] Cancer 104(1): 83-93 (2005)
2003 13	Effectiveness and cost of bisphosphonate therapy in tumor bone disease. [12548587] Cancer 97(3 Suppl): 859-65 (2003)
2003 14	Antitumor effects of bisphosphonates. [12548584] Cancer 97(3 Suppl): 840-7 (2003)
2000 15	Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. [10898355] Cancer 88(12 Suppl): 3080-8 (2000)
2000 16	Cellular and molecular mechanisms of action of bisphosphonates. [10898340] Cancer 88(12 Suppl): 2961-78 (2000)
2006 17	Molecular mechanisms of action of bisphosphonates: current status. [17062705] Clin Cancer Res 12(20 Pt 2): 6222s-6230s (2006)
2003 18	Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. [12855610] Clin Cancer Res 9(7): 2394-9 (2003)
2009 19	Bisphosphonates in oncology: rising stars or fallen heroes. [19179412] Oncologist 14(2): 181-91 (2009)
2004 20	Toward new horizons: the future of bisphosphonate therapy. [15459428] Oncologist 9 Suppl 4(-): 38-47 (2004)
2004 21	Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. [15459427] Oncologist 9 Suppl 4(-): 28-37 (2004)
2004 22	Bisphosphonates: clinical experience. [15459426] Oncologist 9 Suppl 4(-): 14-27 (2004)
2004 23	Bisphosphonates: preclinical review. [15459425] Oncologist 9 Suppl 4(-): 3-13 (2004)
2006 24	Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. [16873332] J Am Dent Assoc 137(8): 1144-50 (2006)
2005 25	Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. [16383048] J Am Dent Assoc 136(12): 1669-74 (2005)
2005 26	Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. [16383047] J Am Dent Assoc 136(12): 1658-68 (2005)
1998 27	Bisphosphonates: mechanisms of action. [9494781] Endocr Rev 19(1): 80-100 (1998)
2006 28	Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. [16702591] Ann Intern Med 144(10): 753-61 (2006)
2009 29	Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. [18987295] Clin J Am Soc Nephrol 4(1): 221-33 (2009)
2006 30	Emerging anti-cancer molecular mechanisms of aminobisphosphonates. [16601276] Endocr Relat Cancer 13(1): 7-26 (2006)
2005 31	Long-term safety of bisphosphonates. [15758064] J Clin Endocrinol Metab 90(3): 1897-9 (2005)
2007 32	Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases. [17396000] J Musculoskelet Neuronal Interact 7(1): 2-8 (2007)
2009 33	Adverse effects of bisphosphonates: implications for osteoporosis management. [19567717] Mayo Clin Proc 84(7): 632-7; quiz 638 (2009)
2008 34	Bisphosphonates: mechanism of action and role in clinical practice. [18775204] Mayo Clin Proc 83(9): 1032-45 (2008)
2007 35	Bisphosphonates: mode of action and pharmacology. [17332236] Pediatrics 119 Suppl 2(-): S150-62 (2007)
2007 36	Bisphosphonates and osteonecrosis of the jaw. [17500074] Rheumatology (Oxford) 46(7): 1049-51 (2007)
2009 37	Bisphosphonate-related osteonecrosis of the jaw: a pictorial review. [19926757] Radiographics 29(7): 1971-84 (2009)
2010 38	Long-term use of bisphosphonates in osteoporosis. [20173017] J Clin Endocrinol Metab 95(4): 1555-65 (2010)
2009 39	Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. [19193912] J Clin Endocrinol Metab 94(2): 373-81 (2009)
2006 40	Bisphosphonate complications including osteonecrosis of the jaw. [17124083] Hematology Am Soc Hematol Educ Program -(-): 356-60, 515 (2006)
2008 41	Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. [18378544] Oncologist 13(3): 330-6 (2008)
2009 42	Bisphosphonates and time to osteonecrosis development. [19897878] Oncologist 14(11): 1154-66 (2009)
2005 43	Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. [15958534] Cancer Res 65(12): 4971-4 (2005)
2008 44	Risks and benefits of bisphosphonates. [18506174] Br J Cancer 98(11): 1736-40 (2008)
2006 45	Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005. [17072246] Med Oral Patol Oral Cir Bucal 11(6): E456-61 (2006)
2008 46	Oral implants in patients receiving bisphosphonates: a review and update. [19047961] Med Oral Patol Oral Cir Bucal 13(12): E755-60 (2008)
2007 47	Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. [17664922] Med Oral Patol Oral Cir Bucal 12(4): E336-40 (2007)
2008 48	Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. [18449117] Med Oral Patol Oral Cir Bucal 13(5): E318-24 (2008)
2010 49	Bisphosphonates in the treatment of metabolic bone diseases. [20485910] Arq Bras Endocrinol Metabol 54(2): 206-12 (2010)
2004 50	A systematic review of the role of bisphosphonates in metastatic disease. [14960258] Health Technol Assess 8(4): 1-176 (2004)
2010 51	Ocular side effects of bisphosphonates: A case report and literature review. [20944044] Can Fam Physician 56(10): 1015-7 (2010)
2007 52	Use of bisphosphonates in prostate cancer: Current status. [19675763] Indian J Urol 23(1): 51-4 (2007)
2007 53	A review of bisphosphonate-associated osteonecrosis of the jaws and its management. [17555652] J Can Dent Assoc 73(5): 417-22 (2007)
2002 54	Actions of bisphosphonates in animal models of breast cancer. [11879558] Breast Cancer Res 4(1): 35-41 (2002)
2002 55	Direct effects of bisphosphonates on breast cancer cells. [11879555] Breast Cancer Res 4(1): 18-23 (2002)
2011 56	Bisphosphonates' : Indications in bone diseases other than osteoporosis. [21681711] Tunis Med 89(6): 511-6 (2011)
2009 57	Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. [19491914] Nat Rev Rheumatol 5(6): 341-6 (2009)
2011 58	What do we know about the ocular adverse effects associated with intravenous bisphosphonates? [21417978] Eklem Hastalik Cerrahisi 22(1): 1 (2011)
2009 59	Bisphosphonate-associated adverse events. [19570737] Hormones (Athens) 8(2): 96-110 (2009)
2011 60	Tumour macrophages as potential targets of bisphosphonates. [22005011] J Transl Med 9(-): 177 (2011)
2010 61	Intravenous bisphosphonates for postmenopausal osteoporosis. [21526078] J Res Med Sci 15(3): 175-84 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Bisphosphonates.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Bisphosphonates.php on line 92